Abstract:Background: The incidence of sleep disorders is more than 27% in the worldwide, and the development of novel sleep drugs that target GABAA receptors is of great interest. Traditional drug screening methods restrict the discovery of lead compounds, the high-throughput screening system is a powerful means for the lead compounds discovery of sleep drug. Methods: The GABAA1-CHO cell line stably expressing α1β2γ2L was constituted by cotransfection of α1, β2 and γ2L subunits into CHO-T-Rex cells. The high-throughput screening method of membrane potential targeting GABAAR was established and optimized. The optimized method was used to screen the compound library, and the compounds with high activity were obtained. The active compounds were confirmed in vitro by electrophysiological detection technique, and the sleep effects of compounds in vivo were detected by pentobarbital sodium sleep model in mice. Results: A stable cell line expressing human GABAA1 receptor in CHO-T-Rex cells was generated and used to establish a functional high-throughput screening assay based on the measurement of membrane potential changes in living cells by fluorometric imaging plate reader (FLIPR). The assay was further used to detect the dose-effect relationships of tool compounds, the EC50 values of agonist GABA (137.42 ± 26.31 nM), positive allosteric modulator diazepam (3.22 ± 0.73 μM), and antagonist gabazine (0.16 ± 0.04 μM), blocking agents bicuculine (0.47 ± 0.06 μM) and PTX (6.39 ± 1.17 μM). In the meanwhile, the compounds were screened from a compound library (10000) by the membrane potential dye assay. Selected 4 active compounds were further identified for their EC50 values in vitro by electrophysiological method, the EC50 values of 4 compounds were further determined as 1.37 ± 0.43 μM, 0.69 ± 0.17 μM, 0.77 ± 0.16 μM, and 1.62 ± 0.29 μM. Furthermore, the pentobarbital sleep rate and the sleep time of mice pretreated with 4 active compounds by oral administration were significantly increased compared with mice pretreated with a negative control in vivo experiment. Conclusion: We successfully generated a stable CHO cell line expressing human GABAA1 by induced expression strategy which decreased cytotoxicity. Then, developed an efficient membrane potential detection method for high-throughput screening, the assay based on the stable cell line could distinguish different types of GABAA1 modulators, which would be an effective in vitro system to screen the GABAAR-targeted compounds. Compared with the patch clamp electrophysiological detection method, the membrane potential detection method has higher detection flux for compounds and higher detection sensitivity for active compounds.

Study on Cell Model for High Throughput Screening the Agonist of Glucagon-Like Petide-1 Receptor

Screening and Identification of A Targeting Peptide to Nglp-1r from Phage Display Peptide Library

Molecular Insights into Ago-Allosteric Modulation of the Human Glucagon-Like Peptide-1 Receptor

A System for Screening Agonists Targeting Β2-Adrenoceptor from Chinese Medicinal Herbs

High cell density cultivation of recombinant Escherichia coli for prodrug of recombinant human GLPs production

Optimization of Fed-batch Culture of Recombinant E.coli. for High Expression of Glucagon Like Peptide-1

Establishment and Application of Cell Model with Stable Expression of hPepT1

[Establishment of High-Throughput Drug Screening Cell Models Based on JAK-STAT Signal Pathway].

Establishment of a High Throughput Screening System for GABAA1 Modulators in Living Cells

A High-Throughput Screening System for G-protein-coupled Receptors Using Β-Lactamase Enzyme Complementation Technology.

Rational design of a GLP-1/GIP/Gcg receptor triagonist to correct hyperglycemia, obesity and diabetic nephropathy in rodent animals

Establishment of hypoglycemic agent screening method based on human glucokinase

Development of a cell-based high-throughput peroxisome proliferator-activated receptors (PPARs) screening model and its application for evaluation of the extracts from Rhizoma Coptis

Development and Characterization of a Fluorescent Probe for GLS1 and the Application for High-Throughput Screening of Allosteric Inhibitors.

Tumor cell membrane-coated continuous electrochemical sensor for GLUT1 inhibitor screening

Establishment of Platform for Screening Insulin-Like Growth Factor-1 Receptor Inhibitors and Evaluation of Novel Inhibitors

Preparation and Preliminary Analysis of Activity of Recombinant GLP-1 Analogue

Design of Glucagon-Like Peptide-1 Receptor Agonist for Diabetes Mellitus from Traditional Chinese Medicine.

Establishment of a CaCC-based Cell Model and Method for High-throughput Screening of M3 Receptor Drugs

Whole organism high content screening identifies stimulators of pancreatic beta-cell proliferation

Development of a high-throughput screening-compatible cell-based functional assay to identify small molecule probes of the galanin 3 receptor (GalR3)